3,4-DIHYDRO-2,7-NAPHTHYRIDINE-1,6(2H,7H)-DIONES AS MEK INHIBITORS

The invention relates to a compound of Formula Ior a pharmaceutically acceptable salt thereof, wherein R1, R2, R3 and R4 are as defined herein. The invention further relates to pharmaceutical compositions comprising such compounds and salts, and to methods and uses of such compounds, salts and compo...

Full description

Saved in:
Bibliographic Details
Main Authors DAHLKE, Joshua Ryan, CLARK, Wesley Dewitt, MORENO, David Austin, KNAPP, Ellen Margaret, DOERNER BARBOUR, Patrick Michael, ALLEN, Shelley, COWDREY, Connor James, BLAKE, James Francis, O'LEARY, Jacob Matthew, REN, Li, KELLUM, Alex Andrew, BLANCHE, Sydney Taylor, WITKOS, Faith Elizabeth, BOYS, Mark Laurence
Format Patent
LanguageEnglish
Published 13.10.2022
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The invention relates to a compound of Formula Ior a pharmaceutically acceptable salt thereof, wherein R1, R2, R3 and R4 are as defined herein. The invention further relates to pharmaceutical compositions comprising such compounds and salts, and to methods and uses of such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer, in a subject in need thereof. The invention further relates to solid forms of 8-((2-fluoro-4-(methylthio)phenyl)amino)-2-(2-hydroxyethoxy)-7-methyl-3,4-dihydro-2,7-naphthyridine-1,6(2H,7H)-dione.
Bibliography:Application Number: US202217708072